Skip to main content
Premium Trial:

Request an Annual Quote

Miraculins Nets $405K in Private Stock Placement

NEW YORK (GenomeWeb News) — Miraculins said yesterday it has pocketed CA$428,000 ($405,000) in a private stock placement by selling 1,222,858 units of certain shares at CA$.35 apiece.
 
The company said in July it could earn as much as CA$500,000 total from the sale by selling 1.25 million units at CA$.40 apiece.
 
Miraculins plans to use the money to fund research and development projects and to replenish working capital coffers.
  
Each unit sold in the offering includes one common share and one and one-half of one share purchase warrant entitling the holder to buy a share for CA$.65 over 12 months after the date of issuance.
The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more